CLRB earnings analysis
What we found in CLRB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing provides no current-quarter income statement, cash-flow, balance-sheet, segment, or EPS figures in the supplied text, so quarter-over-quarter and year-over-year financial trends cannot be assessed. Management is pursuing an FDA NDA for accelerated approval and a potential EMA conditional marketing approval, but explicitly states that existing cash is insufficient to execute this regulatory strategy. Persistent material weaknesses in internal control through June 30, 2026 and the added regulatory-approval risk materially weaken the outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- NDA Submission Strategy
- Management states it plans to submit an NDA to the FDA for accelerated approval of iopofosine I 131 in WM patients who have received two prior lines of therapy, including a BTKi.
- EMA Approval Pathway
- The company is continuing dialogue with the EMA regarding a possible conditional marketing approval submission, following feedback through the EMA scientific advice procedure.
- Material Control Weaknesses Persist
- Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026, due to material weaknesses in internal control over financial reporting that management said existed as of December 31, 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Insufficient Cash for Regulatory Plan
- The company states that existing cash and cash equivalents are not sufficient to execute its regulatory strategy and that additional funds are required before NDA submission and initiation of the proposed confirmatory study.
- Approval of Iopofosine Not Assured
- FDA, EMA, and other regulators may reject or require additional work for the planned NDA or equivalent application; the strategy targets patients who have received two prior lines of therapy, including a BTKi.
- Financial Reporting Control Deficiencies
- Internal-control deficiencies include inaccurate accounting for preferred equity and warrants, stock-based compensation related to restricted stock awards granted in December 2023, and valuation assumptions for preferred warrants. Management said the weaknesses continued through June 30, 2026.
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management states that additional funding is a precursor to NDA submission and initiation of the proposed confirmatory study.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Cellectar Biosciences, Inc. reported a net loss for Q1 2026, with significant focus on advancing its drug development pipeline amid funding challenges. R&D expenses decreased slightly year-over-year, reflecting…
- 10-K · April 30, 2026
- Cellectar Biosciences, Inc. reported a narrower loss for Q4 2025, with an actual EPS of -0.53 compared to an estimate of -1.21, reflecting improved operational management or cost controls. The firm continues to leverage…
- 10-K · March 4, 2026
- Cellectar positions itself as a late-stage clinical biotech leveraging a proprietary phospholipid drug-conjugate (PDC/PRC) platform, with iopofosine I-131 as the lead compound showing strong CLOVER WaM Phase 2 results…
- 10-Q · November 18, 2024
- Cellectar reported a three-month net loss of $14,664,719 (net loss per diluted share $0.40) for the quarter ended September 30, 2024. Cash and equity positions materially improved versus December 31, 2023 (cash…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLRB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever